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Abstract
Background: Chronic hepatitis C virus (HCV) infection can progress to cirrhosis and end-stage liver disease in a
substantial proportion of patients. The infection is frequently asymptomatic, leaving many infected individuals
unaware of the diagnosis until complications occur. This advocates the screening of healthy individuals. The aim of
this study was to estimate the prevalence of HCV infection in the general adult population of the municipality of
Tromsø, Norway, and to evaluate the efficiency of such an approach in a presumed low-prevalence area.
Methods: The study was part of the seventh survey of the Tromsø Study (Tromsø 7) in 2015–2016. Sera from
20,946 individuals aged 40 years and older were analysed for antibodies to HCV (anti-HCV). A positive anti-HCV test
was followed up with a new blood test for HCV RNA, and the result of any previous laboratory HCV data were
recorded. Samples positive for anti-HCV and negative for HCV RNA were tested with a recombinant immunoblot
assay. All HCV RNA positive individuals were offered clinical evaluation.
Results: Among 20,946 participants, HCV RNA was detected in 33 (0.2%; 95% CI: 0.1–0.3), of whom 13 (39.4%; 95%
CI: 22.7–56.1) were unaware of their infection. The anti-HCV test was confirmed positive in 134 individuals (0.6%;
95% CI: 0.5–0.7) with the highest prevalence in the age group 50–59 years. Current or treatment-recovered chronic
HCV-infection was found in 85 individuals (0.4%; 95% CI: 0.3–0.5) and was associated with an unfavorable
psychosocial profile.
Conclusion: In this population-based study, the prevalence of viraemic HCV infection was 0.2%. A substantial
proportion (39%) of persons with viraemic disease was not aware of their infectious status, which suggests that the
current screening strategy of individuals with high risk of infection may be an inadequate approach to identify
chronic HCV infection hidden in the general population.
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Background
Chronic infection with hepatitis C virus (HCV) is a leading
cause of liver cirrhosis, resulting in increased risk of liver fail-
ure, hepatocellular carcinoma (HCC) and premature death
[1]. Globally, an estimated 71 million people are living with
viraemic HCV infection (HCV RNA positive) [2]. Norway is
a low-prevalence country in this respect, as are most other
Western European countries. There are uncertainties
regarding the prevalence of HCV infection in Norway, as
population-based data is limited. A cross-sectional study
based on the Oslo Health Study in 2001 included 11,456 in-
dividuals and reported a prevalence of anti-HCV and HCV
RNA of 0.7 and 0.5%, respectively [3]. In Sweden and
Denmark, the estimated prevalence of chronic HCV infec-
tion is 0.36 and 0.38%, respectively [4, 5].
The incidence of HCV infection is projected to decline,
but the burden of the disease is increasing [6]. According to
a recent modelling approach from Norway, the HCV inci-
dence among people who inject drugs (PWID) peaked in
2000, and has thereafter decreased. However, the occur-
rence of HCV-related cirrhosis and HCC in active and
* Correspondence: hege.kileng@unn.no
1Gastroenterology and Nutrition Research Group, Department of Clinical
Medicine, UiT The Arctic University of Tromsø, 9037 Tromsø, Norway
2Department of Internal Medicine, Section of Gastroenterology, University
Hospital of North Norway, Tromsø, Norway
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kileng et al. BMC Infectious Diseases          (2019) 19:189 
https://doi.org/10.1186/s12879-019-3832-7
former PWID is expected to increase in the coming years
[7]. Prevention of late complications requires treatment in
the early stages of the disease, and the availability of potent
direct-acting antiviral therapies (DAAs) has provided an
opportunity to reverse the rising burden of HCV-related
complications [8].
Surveillance of HCV is challenging for several reasons.
Individuals infected with HCV are often asymptomatic
until a late stage, and it is presumed that up to half of
infected individuals are unaware of their status [5, 9, 10].
A recent modelling study including 28 EU countries, es-
timated that only 36% of those with viraemic HCV infec-
tion have been diagnosed [11].
HCV infection in Norway has by law been a notifiable
disease to The Norwegian Surveillance System for Com-
municable Diseases (MSIS) since 1990. The surveillance
system did not distinguish between resolved and chronic
HCV infection prior to 2016, when it started to include
only HCV RNA positive cases [12]. Yet it still does not
adequately discriminate chronic HCV infection from
acute infection with subsequent spontaneous clearance.
Another limitation of the MSIS registration is the low
notification rate. In a study of HCV treatment uptake
among people who had received opioid substitution
therapy (OST), only 57% of OST patients treated for
HCV infection were notified to MSIS [13]. Notifications
of HCV infection may reflect testing practices rather
than real occurrence of the disease, thus rendering offi-
cial surveillance in Norway incomplete.
In 2016, the World Health Organization (WHO) released
its first global strategy on viral hepatitis aiming to eliminate
HCV as a public health threat by 2030, including an 80%
reduction in new HCV infections and a 65% reduction in
HCV liver-related mortality, requiring diagnosis of 90% and
treatment of 80% of chronically infected patients [14]. Sev-
eral measures are necessary to achieve these goals. Ideally,
screening for HCV infection should identify asymptomatic,
infected persons before they develop cirrhosis and
cirrhosis-related complications. The subsequent early treat-
ment would improve clinical outcomes, reduce transmis-
sion risk and thus save health costs.
Screening strategies vary in different areas, based on the
local epidemiology of HCV infection. In low-prevalence
countries, routine screening of the entire population has not
been considered cost-effective [15–18] and the approach to
prevention and control of HCV infection has focused on
testing persons with risk factors. Recent studies have, how-
ever, indicated that screening of the general population may
be cost-effective compared to risk-based screening [19, 20].
In Norway, a limited screening of high-risk individuals is rec-
ommended, such as current or previous PWID, recipients of
blood products prior to 1992, patients infected with human
immunodeficiency virus (HIV), haemodialysis patients, incar-
cerated individuals, children born to HCV-infected mothers,
individuals with elevated alanine aminotransferase (ALT),
and refugees from endemic regions [21].
In the new treatment landscape with highly effective
and well tolerated DAAs, many countries are reconsider-
ing their testing strategies. Whom and how to screen
has become a prioritized health policy issue.
The Norwegian Ministry of Health and Care recently
launched a national strategy on viral hepatitis with aim of
90% reduction in new HCV infections by 2023 compared
to 2018 [22]. Prevalence studies in the general population
may be an important tool for assessing the number of in-
fected with HCV and thus to enable an estimate of the fu-
ture disease burden. The Tromsø Study is an established
population survey in the municipality of Tromsø in North-
ern Norway, making such a prevalence study feasible.
The primary aim of the present study was to estimate
the prevalence of diagnosed and undiagnosed HCV in-
fection in the general adult population of Tromsø,
Northern Norway, and second, to evaluate the efficiency
of a screening approach to find individuals with undiag-
nosed hepatitis C infection.
Methods
Study population
The study was part of the seventh survey of the Tromsø
Study (Tromsø 7) in 2015–2016. The Tromsø Study is a
longitudinal population-based, prospective study with
repeated health surveys since 1974 in the municipality of
Tromsø in Northern Norway [23]. Tromsø is the largest
city in Northern Norway, harbouring the world’s north-
ernmost university, thus having a high proportion of
young people. The present population (per 2nd quarter
of 2018) is 76,062 inhabitants, predominantly of Norwe-
gian origin (14% immigrants) [24].
Tromsø 7 included more than 50 research projects, cov-
ering various health issues, symptoms and chronic diseases.
HCV detection was included for the first time. Based on
the official population registry, residents of the municipality
of Tromsø aged 40 years and older were invited to partici-
pate. A personal invitation was sent about 2 weeks before a
suggested time of appointment at one permanent study site.
The subjects were free to attend whenever suitable within
the opening hours of the study site and within the one year
duration of the study. The invitation leaflet included all ne-
cessary information, and a questionnaire was enclosed, as
well as username and password for an optional online re-
sponse. Non-attenders were given one reminder. Informa-
tion about the survey and invitation to participate were
repeatedly provided in the local newspapers.
All 32,591 citizens aged 40 years and above were invited,
and 21,083 (65%) attended. Sera from 20,946 participants
(64.3% of invited citizens) were tested for anti-HCV, of
whom 11,004 (52.5%) were women and 9942 (47.5%) were
men. The participation rate was highest in the age group 60
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to 69 years for both women and men, somewhat lower in
younger age groups, and lowest among those older than 80
years (Table 1).
Questionnaire
The participants responded to a self-administered ques-
tionnaire with questions about health, psychological prob-
lems triggering contact to professional health care, anxiety
or depression, smoking habits, alcohol consumption, the
use of drugs other than alcohol, level of education, marital
status and main occupation/activity. There were two ques-
tions regarding hepatitis C (translated from Norwegian):
“Have you been infected with the liver virus hepatitis C?”,
and “If you have been infected with the liver virus hepa-
titis C: have you ever received treatment?”
Data collection and laboratory methods
Sera from 20,946 participants were stored frozen at − 20 °C
and tested for anti-HCV (ARCHITECT Anti-HCV Assay,
Abbott System, Wiesbaden, Germany) at the Department
of Microbiology and Infection Control, University Hospital
of North Norway, Tromsø, Norway. Individuals with a posi-
tive anti-HCV test received an information letter with their
test results, describing the requirement for a second blood
test to discriminate between current infection and previous
exposure to HCV. The second blood test was performed at
the University Hospital in Tromsø, where the result was
followed up by the responsible medical doctor at the De-
partment of Gastroenterology, and compared to any exist-
ing HCV test results. Two reminders were sent to those
who did not have the follow-up test. The follow-up samples
were retested for anti-HCV and further tested for the pres-
ence of HCV RNA (ROCHE RT-PCR Cobas Amplicor
Hepatitis C Viral Polymerase Chain Reaction, Roche Mo-
lecular System Inc., Branchburg NJ, USA). Samples positive
for the anti-HCV test and negative to the HCV RNA test
were analyzed with a recombinant immunoblot assay
(RIBA HCV 3.0 SIA test, Chiron Cooperation, Emeryville,
CA, USA) as a secondary confirmation test of the first line
anti-HCV test to rule out unspecific positive tests. Samples
were considered anti-HCV positive with reactivity to two
or more antigens in the RIBA test, indeterminate when re-
activity to only one antigen was present, which may repre-
sent previous resolved HCV-infection or unspecific
antibody reactions [25], and negative when no
antigen-specific reactivity was observed. The RIBA test was
not carried out in cases were existing laboratory results
were consistent with either spontaneous clearance (previ-
ous positive RIBA test or positive HCV RNA test followed
by at least two consecutive negative HCV RNA tests with
at least three months interval) or obtained sustained viro-
logic response (SVR) after antiviral treatment. HCV geno-
typing was performed as a hybridization assay on products
from the HCV RNA PCR according to the manufacturer’s
instructions (INNO-LIPA HCV II kit, INNOGENETICS,
Ghent, Belgium).
Definitions
The term HCV exposure is used in Tables 2 and 3 to in-
clude individuals with the following characteristics: (1)
persons with chronic (viraemic) HCV infection; i.e. with
positive HCV RNA: (2) persons with treatment-recovered
HCV infection: (3) persons with spontaneously resolved
HCV infection; i.e. with positive RIBA test or positive
HCV RNA test followed by at least two consecutive nega-
tive HCV RNA tests with at least three months interval:
(4) persons with positive anti-HCV test, negative HCV
RNA and indeterminate RIBA test.
Estimated prevalence numbers of HCV exposure and
chronic HCV infection
Estimated prevalence numbers of HCV exposure and
chronic (viraemic) HCV infection in the Tromsø popula-
tion were calculated based on the observed prevalence
in each age group and corrected for different attendance
rates between the groups. An equal prevalence between
attenders and non-attenders was presumed for the cal-
culation of expected numbers of infected individuals.
Clinical follow-up
All subjects with a positive HCV RNA test were offered a
clinical evaluation, which included a thorough medical
Table 1 HCV testing in the Tromsø 7 Study (n = 20,946)
Women Men Total
Age (years) Invited Tested (%) Invited Tested (%) Invited Tested (%)
40–49 5195 3360 (64.7%) 5562 3033 (54.5%) 10,757 6393 (59.4%)
50–59 4534 3230 (71.2%) 4327 2767 (63.9%) 8861 5997 (67.7%)
60–69 3586 2652 (74.0%) 3543 2487 (70.2%) 7129 5139 (72.1%)
70–79 2001 1352 (67.6%) 1897 1310 (69.1%) 3898 2662 (68.3%)
80–89 981 386 (39.3%) 639 322 (50.4%) 1620 708 (43.7%)
90–104 242 24 (9.9%) 84 23 (27.4%) 326 47 (14.4%)
Total 16,539 11,004 (66.5%) 16,052 9942 (61.9%) 32,591 20,946 (64.3%)
Actual numbers for invitation to the Tromsø 7 Study, and rates (n (%)) of testing for anti-HCV according to sex and 10-year age groups
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examination, the recording of the medical history and the
assessment of risk factors for HCV infection. An estimate
of the time-point of transmission was made based on infor-
mation on the first year of high-risk behaviour, such as
injecting drug use (IDU), tattoos or transfusion of blood
products prior to 1992 [26]. At this stage, an additional
blood sample was analysed for platelet count, alanine ami-
notransferase (ALT), and aspartate aminotransferase (AST)
in order to calculate the Fibrosis-4 (FIB-4) index [27]. The
blood sample was also analysed for hepatitis B surface anti-
gen (HBsAg), hepatitis B core antibody (HBcAb) and anti-
gens/antibodies to human immunodeficiency virus (HIV
Ag/Ab combo). Liver stiffness (kPa) was measured with
transient elastography (FibroScan® 402, Echosens, Paris,
France). Significant fibrosis and cirrhosis was defined as
liver stiffness values ≥7 kPa and ≥ 12,5 kPa, respectively,
equivalent to METAVIR fibrosis stage ≥F2 and F4, respect-
ively [28]. Ultrasound was performed at the responsible
medical doctor’s discretion. Treatment was offered to all
HCV RNA positive patients who met for clinical follow-up.
Statistical analysis
Data summaries were performed using SPSS 24.0 software
and Microsoft Excel 2013. The Chi-Square test and
Mann-Whitney U test, as well as multivariate logistic re-
gression analysis, were used to compare sociodemographic
and behavioral characteristics between HCV exposed and
anti-HCV negative. The Fisher’s exact test was used to test
the differences between groups in case of small sample
numbers. A two-tailed p-value < 0.05 was considered sta-
tistically significant.
Results
Prevalence of hepatitis C
Figure 1 shows a flowchart of the study with associated
results. The anti-HCV screening test was positive in 217
(1.0%) of 20,946 individuals. The follow-up test was nega-
tive for anti-HCV and/or RIBA in 83 samples. Thus, the
prevalence of confirmed anti-HCV was 0.6% (95% CI:
0.5–0.7%) (n = 134), with a sex distribution of 71 (53%)
men and 63 (47%) women. HCV RNA was detected in 33
(0.2%; 95% CI: 0.1–0.3) of 20,946 participants, 18 male
(54.5%). Of these viraemic cases, 13 (39.4%; 95% CI: 22.7–
56.1) were not aware of their infection. Two of the 33 per-
sons with current positive HCV RNA reported that they
had received antiviral treatment earlier, one of whom had
interrupted the treatment before scheduled treatment-end
and was considered to be a treatment failure. The second
person did not meet for clinical follow up, rendering it un-
clear whether the vireaemia represents reinfection or
treatment failure. Overall, current or treatment-recovered
HCV infection was found in 85 (0.4%; 95% CI: 0.3–0.5) of
20,946 individuals, 48 (56.5%) men and 37 (43.5%)
women. Of those, 52 (61.2%) had previously received anti-
viral treatment with achieved SVR.
Spontaneous clearance of HCV was demonstrated in 33
(24.6, 95% CI: 17.3–31.9) of 134 anti-HCV positive individ-
uals. The RIBA test was indeterminate in 16 of the cases
that were anti- HCV positive and HCV RNA negative.
Table 2 shows the observed prevalence of HCV expos-
ure and chronic (viraemic) HCV infection according to
sex and 10-year age groups, as well as the estimated
over-all prevalence. The highest prevalence of HCV ex-
posure (1.2%) and chronic HCV infection (0.4%) was
seen in the age group 50–59 years.
HCV genotype
Data on HCV genotype (GT) was available in 75 of the 85
persons with current or recovered chronic HCV infection.
HCV GT 1a was detected in 19 (25.3%) individuals, GT 1b in
10 (13.3%), GT 2b in 10 (13.3%), GT 3a in 33 (44%), GT 4 in
one (1.3%) and GT 1 not available for subtyping in 2 (2.7%).
Unawareness of HCV infection
Thirteen of the 33 (39.4%) individuals with viraemic
HCV infection were not aware of their infectious status,
Table 2 Observed and estimated prevalence of HCV exposure and chronic HCV infection
















40–49 10,757 6393 32 0.5% (0.4–0.7) 54 5 0.08% (0.0–0.2) 8
50–59 8861 5997 69 1.2% (0.9–1.5) 102 24 0.4% (0.2–0.6) 35
60–69 7129 5139 28 0.5% (0.4–0.8) 39 4 0.08% (0.0–0.2) 6
70–79 3898 2662 3 0.1% (0.0–0.3) 4 0 0% (0.0–0.1) 0
80–89 1620 708 2 0.3% (0.1–1.0) 5 0 0% (0.0–0.5) 0
90–104 326 47 0 0% (0.0–7.6) 0 0 0% (0.0–7.6) 0
Total 32,591 20,946 134 0.6% (0.5–0.7) 209 33 0.2% (0.1–0.3) 51
Observed prevalence of HCV exposure and chronic HCV infection in the Tromsø 7 Study according to 10-year age groups. Total prevalence is corrected for
different attendance rate in the different age-groups
aEstimated numbers of individuals in the Tromsø population is based on an equal prevalence between attenders and non-attenders. All numbers are n or
proportions (%) with 95% confidence intervals (95% CI)
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P value ORc (95% CI)
Age (yrs), median (range) 20,946 54 (40–84) 56 (40–99) p = 0.004
Gender (%) 20,946 p = 0.199
Male 71 (53%) 9871 (47%) N.s.
Female 63 (47%) 10,941 (53%)
Live with a spouse/partner (%) 19,767 p < 0.0005
No 50 (43.5%) 4530 (23.1%) N.s.
Yes 65 (56.5%) 15,122 (76.9%)
Level of education (%) 20,573 p = 0.001
< 12 years 85 (64.4%) 10,394 (50.8%) N.s.
> 12 years 47 (35.6%) 10,047 (49.2%)
Disability benefit recipient or unemployed
(%). Retired excluded
15,870 p < 0.0005 2.5 (1.7–3.7)
Yes 46 (36.8%) 1973 (12.5%)
No 79 (63.2%) 13,772 (87.5%)
Self-reported health (%) 20,768 p < 0.0005
Very bad 1 (0.8%) 73 (0.4%) N.s.
Bad 18 (13.6%) 1065 (5.2%)
Neither good nor bad 46 (34.8%) 5353 (25.9%)
Good 61 (46.2%) 11,104 (53.8%)
Excellent 6 (4.5%) 3041 (14.7%)
Psychological problems (%)a 20,251 p < 0.0005
Current 16 (12.9%) 879 (4.4%) N.s.
Previous 12 (9.7%) 1801 (8.9%)
No 96 (77.4%) 17,447 (86.7%)
Daily smoking (%) 20,753 p < 0.0005
Current 54 (40.3%) 2827 (13.7%) 4.4 (2.2–8.6)
Previous 65 (48.5%) 9129 (44.3%) 2.7 (1.4–5.1)
Never 15 (11.2%) 8663 (42.0%)
Alcohol consumption (%) 20,816 p = 0.419
4 or more times a week 5 (3.8%) 1235 (6.0%) N.s.
2–3 times a week 30 (22.6%) 4920 (23.8%)
2–4 times a month 48 (36.1%) 7795 (37.7%)
Monthly or less frequently 34 (25.6%) 5067 (24.5%)
Never 16 (12%) 1666 (8.1%)
Use of drugs other than alcohol (%)b 20,498 p < 0.0005
Yes, now 15 (11.5%) 65 (0.3%) 35.4 (17.4–71.9)
Yes, previously 53 (40.8%) 824 (4.0%) 15.7 (10.2–24.2)
No 62 (47.7%) 19,479 (95.6%)
All numbers are n (%) or median (range). Chi Square, Fisher’s exact or Mann-Whitney U test were used where appropriate
aPsychological problems triggering contact to professional health care
bE.g. cannabis, amphetamines, cocaine, heroin, hallucinogens, solvents, gamma hydroxybutyrate (GHB)
cResults from multivariate logistic regression analysis, adjusted for age and gender, shown as odds ratios (OR) with 95% confidence intervals (CI). N.s.:
Not significant
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corresponding to a population prevalence of 0.06% (95%
CI: 0.03–0.09). Nine of the 13 were women and the me-
dian age was 55 years. The distribution of genotypes 1
through 3 was six GT 1a, two GT 2 and five GT 3a. The
median ALT value was 48 U/L (range 21–276 U/L), with
eight of thirteen persons demonstrating a normal ALT
value. The median liver stiffness value was 6.7 kPa (range
4.1–17.6). Liver stiffness values were < 7 kPa in five per-
sons and between 7 and 12 kPa in six persons. Two per-
sons had liver stiffness > 12.5 kPa, one of whom was
considered to have established liver cirrhosis based on
liver stiffness of 17.6 kPa and signs of cirrhosis on ultra-
sound. The second person had probable liver cirrhosis
based on liver stiffness of 12.6 kPa and a FIB-4 index of
3.86. HBsAg was negative in all, and HBcAb was detected
in three of the 13 persons. In the self-administered ques-
tionnaire, six of the 13 individuals reported current (n = 2)
or past (n = 4) drug injection. In the follow-up examin-
ation, an additional three persons reported past drug in-
jection, thus 69.2% reported a history of IDU. The median
estimated time from infection to diagnosis was 30 years
(range 10–40 years). Extrapolating the observed propor-
tion of individuals who were unaware of their HCV
infection to the whole population of Northern Norway
(484,001 inhabitants) implies that 290 persons above 40
years of age in this region could be unaware of ongoing
HCV infection.
All 13 persons with previously undiagnosed chronic
HCV infection have been successfully treated with
achieved SVR 12 or 24 weeks after completed treatment.
Factors associated with HCV exposure
Frequencies of socio-demographic characteristics in the
HCV-exposed cohort compared to the background
population are shown in Table 3. In univariate analysis,
there was a positive association between HCV exposure
and self-reported bad health, daily smoking, the use of
drugs other than alcohol, lower level of education, living
without a spouse/partner, being disabled or unemployed,
and having psychological problems triggering contact to
professional health care. In a separate question about
anxiety or depression, the HCV-exposed cohort scored
higher than the background population (data not
shown). We found no association between alcohol con-
sumption and HCV infection. In a multivariate logistic
regression analysis including significant variables from
Fig. 1 Flow chart of study design and results
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the univariate analysis and adjusting for age and gender,
significant independent predictors of being exposed to
HCV were: Being disabled or unemployed (OR 2.5; 95%
CI 1.7–3.7), current daily smoking (OR 4.4; 95% CI 2.2–
8.6), previous daily smoking (OR 2.7; 95% CI 1.4–5.1),
current use of drugs other than alcohol (OR 35,4; 95%
CI 17.4–71.9), and previous use of drugs other than al-
cohol (OR 15.7; 95% CI 10.2–24.2).
Estimated cost of screening
Table 4 shows the estimated costs for the screening pro-
ject. The total cost for screening of 20,946 individuals
was NOK 1177705 (€ 125,175), and the cost per newly
detected chronic HCV infection (n = 13) was NOK
90593 (€ 9629).
Discussion
We have carried out a population-based screening for
HCV infection in a presumed low-prevalence area. In clin-
ical practice, the identification of individuals with viraemic
HCV infection is most important. For surveillance pur-
poses, however, reliable data for both current infection
and recovered disease, either spontaneously or through
treatment, is of interest. In this survey of individuals aged
40 years and older, the prevalence of chronic (viraemic)
HCV infection was 0.2%. In comparison, the last popula-
tion survey in Norway in 2001, including people aged 30
years and older, revealed a prevalence of chronic HCV in-
fection of 0.5%, an estimate which also included
treatment-recovered cases [3]. In our study, the prevalence
of current and treatment- recovered chronic HCV infec-
tion was 0.4%, of which a high proportion (61.2%) had
already received treatment with achieved SVR. A model-
ling study in 2013 estimated the viraemic prevalence in
Norway to be 0.43% [29]. The slightly higher estimate in
this study compared to ours might partly be explained by
different study designs, where the modelling study was
based on historical data and expert opinions.
The present study revealed that a substantial proportion
(39.4%) of individuals with chronic HCV infection were un-
aware of their infectious status, a finding which is in line
with the results of others [5, 9–11, 29]. Of the 13 previously
undiagnosed individuals, 69% had a history of IDU, thus
should theoretically have been detected by a risk-based
screening strategy. This suggest that the current recom-
mendation of risk-based screening is suboptimal in identify-
ing all chronically infected persons hidden in the general
population. One reason for this is that infected persons
may not consider themselves as being at risk for HCV in-
fection, i.e. persons with occasional drug use, especially in
the remote past, and individuals who received blood trans-
fusion before 1992 [9, 17]. Others have pointed out that the
stigma associated with IDU; and the socio-demographic
characteristics of PWIDs, create barriers that impede test-
ing and linkage to care in this population [30].
Strengths and weaknesses
The strength of this study is the large sample size in a gen-
eral population, which enhances the probability that the
study population is representative of the general popula-
tion. However, there are important limitations. First, The
Tromsø 7 study only included individuals aged 40 years
and older. This age restriction was inherent to the over-
reaching study design of Tromsø 7, but clearly introduces
a selection bias. IDU is the main mode of transmission of
HCV [31], and it is estimated that 29.8% (range 25.0–34.8)
of PWIDs in Western Europe are younger than 25 years
[32]. In the municipality of Tromsø, it is estimated that
the number of PWIDs is approximately 300 (personal
communication, Inger Hilde Trandem, MD, Social Med-
ical Center, Tromsø, May 28, 2018). There is no clear data
on their age distribution, but it is reasonable to assume
that the proportion of young PWID in Tromsø is compar-
able to the findings in the above mentioned study. Due to
the age restriction, the prevalence of HCV infection in our
study is most likely underestimated.
Table 4 Cost of screening for HCV in the Tromsø 7 Study
Cost per analysis Analyses (n) Total cost Cost per newly detected chronic
HCV infection (n = 13)
Reagentsa 20,946 NOK 922705
(GBP 86,987, € 98,071)
NOK 70977
(GBP 6691, € 7544)
Labour costsb NOK 180000
(GBP 16,969, € 19,132)
NOK 13846
(GBP 1305, € 1472)
Otherc NOK 75000
(GBP 7071, € 7972)
NOK 5769
(GBP 544, € 613)
Total NOK 56.23
(GBP 5.30, € 5.98)
20,946 NOK 1177705
(GBP 111,028, € 125,175)
NOK 90593
(GBP 8541, € 9629)
Estimated costs for the HCV screening project in Norwegian Kroner (NOK), Pounds (GBP) and Euros (€). 1 GBP and 1 € approximated 10.69 and 9.48 NOK,
respectively, as of 2. October 2018. 1 € = 1.15 US Dollars
aReagents (anti-HCV test kits) for this study were provided by Abbvie AS, Norway. Cost is based on prices for test kits used for daily routine HCV testing
bLabour costs in this study were covered by the Northern Norway Regional Health Authorities with the sum mentioned, which was based on estimated time used
for testing the samples in the study
cParticipation fee for the Tromsø 7 Study
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Second, even if participation rates were generally high
across all age groups, self-selection is still an important
issue that may affect the representativeness of the study
sample. The attenders in population surveys tend to be
more educated and have a healthier life style than
non-attenders [33]. The second survey of the Tromsø
study (Tromsø 2) showed that various psychiatric disor-
ders and alcohol abuse were significant predictors of non-
attendance in health surveys [34], and a Canadian study
demonstrated that non-response bias is a problem in alco-
hol and drug use surveys [35]. It is therefore reasonable to
assume that current and former PWIDs are less likely to
participate in health surveys, also resulting in underesti-
mation of the true HCV prevalence and reducing the effi-
ciency of screening in the general population.
The interpretation and significance of indeterminate
RIBA reactions are unclear. In one study, 4.9% of RIBA
indeterminate cases were found to be HCV RNA posi-
tive [36]. Still, most individuals with indeterminate RIBA
have a negative HCV RNA test, which may represent
previous resolved HCV-infection as well as unspecific
antibody reactions [25]. Reports have shown that ap-
proximately half of those with indeterminate RIBA have
a resolved HCV infection [37, 38]. In this study, we have
chosen to include persons with RIBA indeterminate re-
sult in the HCV-exposed cohort, which could have led
to overestimation of anti-HCV positive. However, the
number of RIBA-indeterminate records was low, making
the contribution of these less important.
Screening strategies in a low-prevalence area: Whom and
how to screen
Our study was integrated in an established
population-based survey with repeated health surveys
since 1974. The attendance rate was 64.3% and the esti-
mated cost per newly detected chronic HCV infection was
approximately NOK 90000 (€ 9629). HCV-screening of
the general population outside such an established popu-
lation survey would have been more laborious and at an
expected considerably higher costs, thus making it less
feasible. As discussed above, it is likely that persons be-
longing to risk groups for HCV infection attended the
study to a lesser degree than the general population, redu-
cing the efficiency of such an approach. On the other
hand, the study has unmasked several individuals with
chronic HCV infection that did not define themselves as
belonging to known risk groups. A recent Spanish pilot
study for an eventual population-based screening program
included the adult population (20–75 years) in a small
health area with a participation rate of 46.2% (2637/5706)
[39]. HCV RNA was detected in 13 persons (0.5%), of
whom five were unaware of the disease.
In low-prevalence countries, routine screening of the en-
tire population has not been considered to be cost-effective
[15–18], and screening are limited to high-risk populations.
However, the high proportion of undiagnosed HCV infec-
tion clearly underscores the limitations of the risk-based
screening approach and the need to reconsider screening
strategies in order to achieve the diagnosis rate of 90% pro-
moted by the WHO.
In the US, it is recommended a one-time screening of
persons in the high-prevalence 1945–1965 birth cohort, in
addition to targeted risk-based testing [40]. In the present
study, the highest prevalence of anti-HCV and viraemic
HCV infection was found in the age group 50–59 years,
i.e. in people born between 1956 and 1965, which may be
explained by a later onset of the epidemic of IDU in
Norway, with a gradual increase in the number of PWID
from the onset of IDU in 1973 until a peak was reached in
2000 [7]. In a birth-cohort analysis, 73% of the
HCV-infected population in Norway was born between
1955 and 1980 [41]. A systematic review including several
countries concluded that screening of birth cohorts, drug
users, and high-risk populations was cost-effective [18].
However, recent studies indicate that universal screening
of the general population may be an effective strategy. In
France, where the prevalence of chronic HCV infection is
0.3% [2], a modelling study showed that universal screen-
ing of all individuals aged 18–80 years was the most effect-
ive screening strategy, and also the most cost-effective,
assuming rapid initiation of treatment after diagnosis [19].
Likewise, in Spain with an HCV RNA prevalence 0.35–
0.41%, a recent modelling study concluded that screening
of the general adult population would identify a larger
number of additional individuals with chronic HCV infec-
tion than screening high-risk groups or screening the
age-cohort with the highest anti-HCV prevalence plus
high-risk groups [20].
Others suggest strategies to improve targeted screening
of people in high-risk groups in various settings. Primary
care practitioners can play an important role in targeted
screening, especially in former PWID, whereas screening
of current PWID is more appropriate in settings like out-
patient clinics, opioid substitution programs, jails, and
psychiatric clinics [17, 42–46]. In a screening and medical
follow-up programme in Northern Norway, primary care
practitioners were encouraged to screen patients with
former or present risk factors for HCV infection, which
led to an increase in the number of newly diagnosed HCV
infections in the subsequent years [47]. Technical bottle-
necks in HCV testing can lead to missed opportunities in
the HCV cascade of care, e.g., when a high proportion of
anti-HCV positive individuals are not followed up with a
confirmatory test for HCV RNA [48]. The availability of a
new point-of-care (PoC) test with high sensitivity and spe-
cificity (close to 100%) for detection of HCV RNA might
contribute to simplification of HCV testing and thus en-
able decentralisation of HCV care and treatment [49].
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New technology, such as the use of dried blood spot and
saliva sampling could increase access to HCV testing, e.g.
in people with difficult venous access [50, 51].
There are potential negative effects associated with
screening large numbers of persons in a population with
low prevalence of HCV infection. In our study, the pro-
portion of false positive anti-HCV tests was 38.2% (83/
217). False-positive results can cause harm by way of
anxiety and stigmatization, although such effects are dif-
ficult to quantify [52].
Implications
Modelling studies have indicated that screening in the
general adult population may be an effective screening
strategy [19, 20]. Universal screening may allow diagnosis
and treatment of asymptomatic infected persons, avoiding
the development of complications and onward transmis-
sion, thus saving health costs. To be effective, people with
the highest risk of infection must also attend the screening
project. Based on this, strategies to improve targeted
screening of people in high-risk groups in various settings,
including primary care-based interventions, may still be
the most effective approach in low-prevalence regions. To
overcome the high costs associated with screening in the
general population, the use of a birth-cohort screening
strategy could be considered, which in our case would be
based on the finding of the highest prevalence of
anti-HCV and chronic HCV infection in people born be-
tween 1956 and 1965. Finally, implementation of simpli-
fied testing methods may increase access to HCV testing
in both risk groups and birth cohorts.
Conclusion
In this population-based survey the prevalence of chronic
HCV infection in the general population in Tromsø was
0.2%, but due to biases the true prevalence is likely higher.
A substantial proportion (39.4%) of individuals with vir-
aemic infection was not aware of their diagnosis, suggest-
ing that the current recommendation of screening of
individuals with high risk of infection is an inadequate
approach to identify all chronically infected persons.
Strategies to improve HCV awareness and case-finding
are needed, and for some communities, testing the general
population may be a sensible approach.
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